Skip to main content
SpringerLink
Log in

Regulatory watch

Impact of scientific advice from the European Medicines Agency

  • Biobusiness Briefs
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Impact of scientific advice.

Acknowledgements

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Author information

Authors and Affiliations

  1. European Medicines Agency, 30 Churchill Place, London, E14 5EU, Canary Wharf, UK

    Matthias P. Hofer, Christina Jakobsson, Nikolaos Zafiropoulos, Spiros Vamvakas, Thorsten Vetter & Jan Regnstrom

  2. Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, London, SW1W 9SZ, Victoria, UK

    Robert J. Hemmings

Authors
  1. Matthias P. Hofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Jakobsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikolaos Zafiropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Spiros Vamvakas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thorsten Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan Regnstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert J. Hemmings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Regnstrom.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Definitions and data analysis (PDF 140 kb)

Supplementary information S2 (table)

Summary of MAA submissions, SA requests and compliance with SA by year (PDF 107 kb)

Supplementary information S3 (table)

MAA procedure time and the number of MOs in relation to compliance with SA on clinical trial design (PDF 97 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hofer, M., Jakobsson, C., Zafiropoulos, N. et al. Impact of scientific advice from the European Medicines Agency. Nat Rev Drug Discov 14, 302–303 (2015). https://doi.org/10.1038/nrd4621

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4621

  • Springer Nature Limited

This article is cited by

Search

Navigation